The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

A new study suggests implementation of a low-cost clinical decision support tool reduces hypoglycemia risk in older adults with type 2 diabetes.

When cognitively healthy older adults performed a road test when taking a medicine with adverse effects, 35% of participants received a marginal/fail rating.

More than 90% of patients with CDI treated with WMT achieved clinical cure, while only 3.8% of WMTs resulted in adverse events.

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.

A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.

Investigators believe their findings may help reduce the negative of self-stigma and subjective symptom reporting burdening patients with depression.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019.

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment.

This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

This set of measures may promote a more accurate assessment of HS in patients as well as on their life outcomes, with the goal being shared decision-making in clinical practice.

This action represents the first occurrence of the FDA pursuing civil money penalties for the maximum amount against e-cigarette retailers for such an offense.

Patients with rheumatoid arthritis have a heightened risk of interstitial lung disease, but how should clinicians treat the disease when first diagnosed? Test your knowledge with this quiz.

Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

The FDA warns semaglutide (Ozempic) users of increased ileus risk and hypoglycemia with insulin secretagogues.

A new study reveals pleasant stimuli brings less joy to people with schizophrenia or those who have a risk of psychosis.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

Dr Chee Kay Cheung is sharing his expertise on treating patients with IgA nephropathy. He discusses newly approved treatments, as well as exciting novel immune modulating therapies that are on the horizon.